<DOC>
	<DOCNO>NCT02751554</DOCNO>
	<brief_summary>The purpose study help develop special PET/CT scan help investigator develop new drug see drug go body long stay diseased normal tissue . The drug call PU-AD . In study , investigator give tiny dose PU-AD , dose expect much small affect disease . This tiny dose label ( attach ) small amount radiation ( call Iodine-124 124I ) investigator follow go body use PET/CT scanner . Doing help investigator figure best give high dos PU-AD patient future , help investigator see tiny dose PU-AD radiation ( 124I-PU-AD ) might use future detect disease use PET/CT scanner .</brief_summary>
	<brief_title>PET Imaging Patients Using 124I-PU-AD</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Age 2190 year old . Negative serum pregnancy test female childbearing age ( 1150 year ) and/or lack childbearing potential . No breastfeeding . Patients diagnosis cancer and/or Alzheimer 's Disease , meet trial eligibility criterion specify either disease . For cancer patient : Patients eligible histologic type cancer . Eligible histologic type cancer type include solid malignancy , myeloma , lymphoma . Cancer histology confirm MSKCC Department Pathology . Cancerous disease radiologicallymeasurable evaluable define publish tumor response criterion ( include limit RECIST 1.1 ) . For Alzheimer 's Disease patient : Established diagnosis mildmoderate Alzheimer 's disease base upon neurological neuropsychological evaluation follow National Institute Aging Alzheimer 's disease Association criterion recently revisit NINCDSADRDA criterion . Citation : PMID : 21514250 Documentation diagnosis mildmoderate Alzheimer 's disease , , boardcertified neurologist ( MSKCC nonMSKCC ) Patient appoint health care proxy specifically designate research consent appointment document . Patient designate athome caregiver ( ) responsible provide daily medication patient , document patient 's daily dos SSKI oral medication , 2 week per study protocol . For patient cancer Alzheimer 's Disease , patient consider eligible meet eligibility requirement either Alzheimer 's Disease cancer patient , specify . Previous allergic reaction Xray CT iodinate contrast medium . Hypersensitivity iodide product . Known hyperthyroidism Hepatic : Bilirubin &gt; 1.5 x institutional upper limit normal ( ULN ) AST/ALT &gt; 2.5 x ULN Albumin &lt; 2 g/dl GGT &gt; 2.5 x ULN IF Alkaline phosphatase &gt; 2.5 x ULN Renal : Creatinine &gt; 1.5 x ULN creatinine clearance &lt; 60 mL/min Acute major illness ( e.g. , unstable cardiovascular condition . ) Patient inability give consent personally via appoint health care proxy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>124I-PU-AD</keyword>
	<keyword>PET Imaging</keyword>
	<keyword>16-004</keyword>
</DOC>